What is the recommended steroid therapy for acute or chronic rhinosinusitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Steroid Therapy for Rhinosinusitis

For acute bacterial rhinosinusitis, intranasal corticosteroids (mometasone, fluticasone, or budesonide) twice daily are strongly recommended as adjunctive therapy to antibiotics, while for chronic rhinosinusitis, intranasal corticosteroids combined with saline irrigation form the cornerstone of medical management. 1, 2


Acute Rhinosinusitis (ARS)

Intranasal Corticosteroids – Primary Adjunctive Therapy

  • Intranasal corticosteroids (INCS) should be added to antibiotic therapy in all patients with acute bacterial rhinosinusitis to reduce mucosal inflammation and accelerate symptom resolution; this recommendation is supported by strong evidence from multiple randomized controlled trials. 1, 2, 3

  • Preferred agents include mometasone furoate, fluticasone propionate, or budesonide administered twice daily (2 sprays per nostril), as these have negligible systemic bioavailability and superior safety profiles. 2, 4, 5

  • Treatment duration for acute bacterial sinusitis is 15–21 days, concurrent with the prescribed antibiotic course. 2

  • INCS provide modest but clinically meaningful symptom relief when added to antibiotics: a Cochrane review showed that adding intranasal steroids increased symptom improvement from 66% to 73% after 15–21 days (NNT = 14). 2

  • In patients with recurrent acute or chronic sinusitis, fluticasone combined with antibiotics raised treatment success from 74% to 93% at 3 weeks; this effect was not observed in sporadic acute bacterial sinusitis without a history of recurrence. 2

Systemic (Oral) Corticosteroids – Limited Role

  • Oral corticosteroids are reasonable only for patients who fail to respond to initial antibiotic treatment, demonstrate nasal polyposis, or have marked mucosal edema, with a typical short-term duration of 5–7 days. 1, 3, 6

  • The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) guidelines advise against routine use of systemic corticosteroids in patients with acute post-viral rhinosinusitis due to limited benefits that disappear by 10–12 weeks and potential harm. 2

  • For acute hyperalgic sinusitis (severe pain), short-term oral corticosteroids (e.g., dexamethasone 4 mg or prednisone 40–60 mg daily for 5–7 days) may be used as adjuvant therapy when combined with appropriate antibiotic therapy. 3

  • Systemic corticosteroids must never be given without concurrent antibiotics when bacterial sinusitis is suspected, as this may suppress the immune response and allow bacterial proliferation. 3

Administration Technique and Safety

  • Patients should be carefully instructed to direct sprays away from the nasal septum to minimize local side effects such as nasal irritation and bleeding. 2

  • The nasal septum should be periodically examined to ensure there are no mucosal erosions. 2

  • When used at recommended doses, INCS are not generally associated with clinically significant systemic side effects. 2, 5


Chronic Rhinosinusitis (CRS)

Intranasal Corticosteroids – First-Line Therapy

  • Intranasal corticosteroids are the most effective medication class for controlling nasal congestion, rhinorrhea, and inflammation in chronic rhinosinusitis, and should be the primary corticosteroid therapy. 1, 2, 7

  • For CRS without nasal polyps, INCS should be used for a minimum of 8–12 weeks, with continuation long-term if clinically beneficial. 2

  • For CRS with nasal polyps, topical corticosteroid drops (not sprays) should be used for 3 months, extending therapy if it remains helpful. 2

  • INCS should be combined with high-volume saline nasal irrigation (hypertonic 3–5% solution) for enhanced effectiveness, as recommended by the American College of Allergy, Asthma, and Immunology. 2

  • Recent evidence shows that topical steroids delivered via exhalation delivery system (EDS) or sinonasal catheter are significantly more effective than traditional sprays for CRSsNP, with EDS achieving an odds ratio of 3.4 for treatment response compared to placebo. 8

  • Nebulized budesonide is effective at half dose compared to budesonide irrigation in CRS, providing an alternative delivery method. 9

Systemic (Oral) Corticosteroids – Selective Use

  • For severe chronic sinusitis with nasal polyps, consider a short course (5–7 days) of oral corticosteroids (prednisone 40–60 mg daily, then taper over 7–14 days) in addition to INCS. 2, 10

  • The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 recommends oral prednisolone in dosages ranging from 25–60 mg for 7–20 days, showing significant symptom improvement in patients with chronic sinusitis with nasal polyps. 2

  • Short courses of systemic corticosteroids combined with intranasal corticosteroids show significant but temporary benefit for CRS with nasal polyps, with a significant reduction in total symptom score at 2–4 weeks (SMD -1.51), though benefits disappear by 10–12 weeks. 2

  • There is no evidence supporting oral corticosteroids for chronic rhinosinusitis without nasal polyps; treatment should focus on intranasal corticosteroids (used for at least 8–12 weeks) plus saline irrigation. 2

  • Oral corticosteroids should never be used as monotherapy, but always combined with intranasal corticosteroids, antibiotics when bacterial infection is documented, and saline nasal irrigation. 2

Post-Operative Management

  • INCS should be continued postoperatively in patients who undergo endoscopic sinus surgery, as recommended by the American College of Allergy, Asthma, and Immunology. 2

Practical Considerations

When to Reassess and Refer

  • If symptoms do not improve after 3–4 weeks of appropriate INCS therapy, consider referral to a specialist (otolaryngologist or allergist-immunologist) for further evaluation of underlying allergic rhinitis, immunodeficiency, or anatomical abnormalities. 2

  • For patients with recurrent sinusitis (≥3 episodes per year), evaluate for underlying inflammation, allergy, immunodeficiency, and anatomic abnormalities. 3

Common Pitfalls to Avoid

  • Failure to use proper technique can reduce efficacy and increase side effects; ensure patients understand correct administration method (aim away from septum, use after nasal saline irrigation for better penetration). 2

  • Using oral steroids without concurrent intranasal corticosteroids fails to maintain benefits after the oral course ends. 2

  • Using fixed low doses of oral steroids rather than starting higher and tapering deviates from evidence-based protocols. 2

  • Rhinitis medicamentosa is not a concern with INCS, unlike with topical decongestants which should not be used for more than 3 days. 2, 7

Special Populations

  • For patients with asthma, exercise caution when using oral corticosteroids due to high overall steroid burden. 2

  • In immunocompromised patients, exercise caution with systemic corticosteroids. 2

  • Topical antifungal agents (systemic or topical) should not be used for chronic rhinosinusitis. 1


Algorithm for Steroid Selection

  1. Acute bacterial rhinosinusitis confirmed (persistent ≥10 days, severe ≥3–4 days, or "double sickening"):

    • Start INCS (mometasone, fluticasone, or budesonide) twice daily + antibiotics
    • Continue INCS for 15–21 days
    • Add oral steroids (5–7 days) only if marked mucosal edema or treatment failure
  2. Chronic rhinosinusitis without polyps:

    • INCS twice daily + saline irrigation (minimum 8–12 weeks)
    • Consider EDS or nebulized delivery if traditional spray fails
    • No role for oral steroids
  3. Chronic rhinosinusitis with nasal polyps:

    • INCS drops (not spray) for 3 months + saline irrigation
    • Add short course oral steroids (prednisone 40–60 mg daily for 5–7 days, then taper) for severe symptoms
    • Continue INCS long-term after oral course
  4. Post-operative CRS:

    • Continue INCS indefinitely

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intranasal Corticosteroid Spray Treatment for Sinusitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Acute Bacterial Sinusitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Intranasal steroid therapy - EPOS 2020.

Otolaryngologia polska = The Polish otolaryngology, 2020

Research

Contemporary Use of Corticosteroids in Rhinology.

Current allergy and asthma reports, 2017

Guideline

Chronic Sinus Congestion Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended management for sphenoid sinusitis?
What is the first‑line medication for acute bacterial sinusitis?
What are the likely diagnoses and recommended work‑up and treatment for a patient with a one‑month history of progressively worsening right posterior oropharyngeal pain radiating to the ear, pain on swallowing, new right facial pressure and headache, a history of sinusitis, and negative rapid streptococcal test and neck ultrasound?
What is the recommended management for an acute sinus infection?
What is the best approach for managing sinus pain and pressure in a patient with EOE, obesity, allergies, and HTN, and is a Medrol pack appropriate?
What is the appropriate treatment for an elderly patient with dementia who has an intestinal tapeworm identified in stool?
In a patient with three thyroid nodules, one of which has increased to 2 cm, normal TSH, free T3 and free T4, and who stopped suppressive levothyroxine therapy, should a fine‑needle aspiration be performed now or should levothyroxine be restarted?
What is the appropriate next management for an 81‑year‑old woman with type 2 diabetes, hemoglobin A1c 6.9%, impaired renal function (elevated BUN, reduced eGFR) and significant albuminuria/proteinuria who is currently taking atenolol, aspirin, atorvastatin, gabapentin, insulin, semaglutide, and valsartan (Diovan)?
Why might a patient experience weight gain while being treated with tirzepatide?
What is the appropriate enoxaparin (Clexane) dose for a patient with non‑ST‑elevation myocardial infarction based on their estimated glomerular filtration rate?
How should I treat tardive dyskinesia caused by Zofran (ondansetron)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.